市場調查報告書

搭配診斷的全球市場:各技術類型及適應症機會分析、產業預測(2019年∼2026)

Companion Diagnostics Market by Technology Type, and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 908539
出版日期 內容資訊 英文 199 Pages
商品交期: 2-3個工作天內
價格
Back to Top
搭配診斷的全球市場:各技術類型及適應症機會分析、產業預測(2019年∼2026) Companion Diagnostics Market by Technology Type, and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2019年07月06日內容資訊: 英文 199 Pages
簡介

全球搭配診斷市場,2018年達到16億7,800萬美元的規模,從2019年預計將以18.3%的年複合成長率成長,預計到2026年達到64億5,200萬美元的規模。

本報告涵括全球搭配診斷市場,透過對市場成長促進因素和市場機會,市場趨勢,以及企業策略等廣泛調查,來進行詳細的市場現狀分析以及未來預測。

目錄

第1章 簡介

  • 報告概要
  • 對利害關係者而言的主要優點
  • 主要市場區隔
    • 主要企業的清單
  • 調查方法
    • 二次調查
    • 一次調查
    • 分析工具及模式

第2章 摘要整理

  • 調查結果
  • 主要調查結果
    • 主要的投資財源
    • 主要的影響因素
  • CXO的觀點

第3章 市場概要

  • 市場定義和範圍
  • 搭配診斷產業/市場形成的主要因素
    • 供應商談判力:中
    • 新加入廠商的威脅:高
    • 替代品的威脅:低
    • 競爭對手的威脅:中
    • 買主談判力:中
  • 父母/PEER市場概要
  • 市場演進/產業藍圖
  • 搭配診斷相關政府的法規
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第4章 各技術市場

  • 概要
    • 市場規模與預測
  • 免疫組織化學
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 聚合酵素鏈鎖反應(PCR)
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 次世代定序(NGS)
    • 市場規模與預測:各地區
    • 市場分析:各國
  • In situ混合形成法
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 其他
    • 市場規模與預測:各地區
    • 市場分析:各國

第5章 各適應症市場

  • 概要
    • 市場規模與預測
  • 腫瘤學
    • 主要的市場趨勢與機會
    • 市場規模與預測:各類型
    • 市場規模與預測
    • 市場分析:各國
  • 神經學
    • 市場規模與預測
    • 市場分析:各國
  • 其他
    • 市場規模與預測
    • 市場分析:各國

第6章 各地區市場

  • 概要
    • 市場規模與預測
  • 北美
    • 主要的市場趨勢,成長要素,機會
    • 市場規模與預測:各國
    • 北美的市場規模與預測:各技術
    • 北美市場規模與預測:各適應症
  • 歐洲
    • 主要的市場趨勢,成長要素,機會
    • 市場規模與預測:各國
    • 歐洲的市場規模與預測:各技術
    • 歐洲市場規模與預測:各適應症
  • 亞太地區
    • 主要的市場趨勢,成長要素,機會
    • 市場規模與預測:各國
    • 亞太地區的市場規模與預測:各技術
    • 亞太地區的市場規模與預測:各適應症
  • 南美、中東、非洲
    • 主要的市場趨勢,成長要素,機會
    • 市場規模與預測:各國
    • LAMEA的市場規模與預測:各技術
    • LAMEA市場規模與預測:各適應症

第7章 有競爭力的景觀

  • 簡介
    • 市場企業的定位,2018年
  • 最優秀策略
  • 競爭儀表板
  • 競爭熱圖

第8章 企業概要

  • Abbott Laboratories Molecular, Inc.
  • Agilent (Dako Denmark A/S)
  • ARUP Laboratories, Inc.
  • BioMerieux
  • Danaher Corporation (Leica Microsystems)
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • Roche (Ventana Medical Systems, Inc)
  • Thermo Fisher Scientific (Life Technologies Corporation)
  • QIAGEN N.V.
目錄
Product Code: LI_183735

The global companion diagnostics market generated $1,678 million in 2018, and is projected to reach $6,452 million by 2026, growing at a CAGR of 18.3% from 2019 to 2026.

Companion diagnostic is a medical device, often an in-vitro device that provides information essential for the safe and effective use of a corresponding drug or biological product. These tests help a health care professional to determine patients who can benefit from a particular therapeutic product, identify patients at increased risk of severe side effects as a result of the treatment with a particular therapeutic product as well as achieve improved safety or effectiveness.

The companion diagnostics market is expected to experience significant growth during the forecast period owing to growth in demand for advanced therapies, rise in R&D activities to develop low cost & highly efficient drugs, increase in awareness in personalized medicines and surge in demand for cost effective diagnosis are some factors that majorly drive the market growth.

The global companion diagnostics market is segmented based on technology, indication, and region. Based on technology, the market is categorized as immunohistochemistry, polymerase chain reaction (PCR), next Generation Sequencing (NGS), in situ hybridization, and others. On the basis of indication, it is segmented into oncology, neurology, and others. Oncology is further classified into lung cancer, colorectal cancer, breast cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Technology Type

  • Immunohistochemistry
  • Polymerase chain reaction (PCR)
  • Next Generation Sequencing (NGS)
  • In situ hybridization
  • Others
  • Indication
  • Oncology
  • Lung cancer
  • Colorectal cancer
  • Breast cancer
  • Blood cancer
  • Others
  • Neurology
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Abbott Laboratories Molecular, Inc.
  • Agilent (Dako Denmark A/S)
  • ARUP Laboratories, Inc.
  • BioMerieux SA
  • Danaher Corporation (Leica Microsystems)
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Roche (Ventana Medical Systems, Inc.)
  • Thermo Fisher Scientific (Life Technologies Corporation)

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

  • Resonance Health Ltd

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
  • 2.2. Key findings
    • 2.2.1. Top investment pockets
    • 2.2.2. Top impacting factors
  • 2.3. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key forces shaping companion diagnostics industry/market
    • 3.2.1. Moderate power of suppliers
    • 3.2.2. High threat of new entrants
    • 3.2.3. Low threat of substitution
    • 3.2.4. Moderate competitive rivalry
    • 3.2.5. Moderate power of buyers
  • 3.3. Parent/ peer market overview
  • 3.5. Market evolution/industry roadmap
  • 3.6. Government regulations for companion diagnostics
  • 3.7. Market dynamics
    • 3.7.1. Drivers
      • 3.7.1.1. Increased popularity of personalized medicine
      • 3.7.1.2. Increase in cases of adverse drug reactions (ADRs)
      • 3.7.1.3. Surge in healthcare expenditure worldwide
      • 3.7.1.4. Technological advancements in diagnostic techniques
    • 3.7.2. Restraints
      • 3.7.2.1. Unfavorable reimbursement policies in some countries
    • 3.7.3. Opportunities
      • 3.7.3.1. Growth opportunities in emerging markets
      • 3.7.3.2. Increase in incidence of cancer across the globe
    • 3.7.4. Impact analysis

CHAPTER 4: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Immunohistochemistry
    • 4.2.1. Market size and forecast, by region
    • 4.2.2. Market analysis, by country
  • 4.3. Polymerase chain reaction (PCR)
    • 4.3.1. Market size and forecast, by region
    • 4.3.2. Market analysis, by country
  • 4.4. Next generation sequencing (NGS)
    • 4.4.1. Market size and forecast, by region
    • 4.4.2. Market analysis, by country
  • 4.5. In situ hybridization
    • 4.5.1. Market size and forecast, by region
    • 4.5.2. Market analysis, by country
  • 4.6. Others
    • 4.6.1. Market size and forecast, by region
    • 4.6.2. Market analysis, by country

CHAPTER 5: COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oncology
    • 5.2.1. Key market trends and opportunities
    • 5.2.2. Market size and forecast, by type
      • 5.2.2.1. Lung cancer
      • 5.2.2.1.1. Market size and forecast
      • 5.2.2.2. Colorectal cancer
      • 5.2.2.2.1. Market size and forecast
      • 5.2.2.3. Breast cancer
      • 5.2.2.3.1. Market size and forecast
      • 5.2.2.4. Blood cancer
      • 5.2.2.4.1. Market size and forecast
      • 5.2.2.5. Others
      • 5.2.2.5.1. Market size and forecast
    • 5.2.3. Market size and forecast
    • 5.2.4. Market analysis, by country
  • 5.3. Neurology
    • 5.3.1. Market size and forecast
    • 5.3.2. Market analysis, by country
  • 5.4. Others
    • 5.4.1. Market size and forecast
    • 5.4.2. Market analysis, by country

CHAPTER 6: COMPANION DIAGNOSTICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. Market size and forecast, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. companion diagnostics market, by technology
      • 6.2.2.1.2. U.S. companion diagnostics market, by indication
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada companion diagnostics market, by technology
      • 6.2.2.2.2. Canada companion diagnostics market, by indication
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Mexico companion diagnostics market, by technology
      • 6.2.2.3.2. Mexico companion diagnostics market, by indication
    • 6.2.3. North America market size and forecast, by technology
    • 6.2.4. North America Market size and forecast, by indication
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Market size and forecast, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany companion diagnostics market, by technology
      • 6.3.2.1.2. Germany companion diagnostics market, by indication
      • 6.3.2.2. France
      • 6.3.2.2.1. France companion diagnostics market, by technology
      • 6.3.2.2.2. France companion diagnostics market, by indication
      • 6.3.2.3. UK
      • 6.3.2.3.1. UK companion diagnostics market, by technology
      • 6.3.2.3.2. UK companion diagnostics market, by indication
      • 6.3.2.4. Rest of Europe
      • 6.3.2.4.1. Rest of Europe companion diagnostics market, by technology
      • 6.3.2.4.2. Rest of Europe companion diagnostics market, by indication
    • 6.3.3. Europe market size and forecast, by technology
    • 6.3.4. Europe Market size and forecast, by indication
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan companion diagnostics market, by technology
      • 6.4.2.1.2. Japan companion diagnostics market, by indication
      • 6.4.2.2. China
      • 6.4.2.2.1. China companion diagnostics market, by technology
      • 6.4.2.2.2. China companion diagnostics market, by indication
      • 6.4.2.3. Australia
      • 6.4.2.3.1. Australia companion diagnostics market, by technology
      • 6.4.2.3.2. Australia companion diagnostics market, by indication
      • 6.4.2.4. Rest of Asia-Pacific
      • 6.4.2.4.1. Rest of Asia-Pacific companion diagnostics market, by technology
      • 6.4.2.4.2. Rest of Asia-Pacific companion diagnostics market, by indication
    • 6.4.3. Asia-Pacific market size and forecast, by technology
    • 6.4.4. Asia-Pacific Market size and forecast, by indication
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. Market size and forecast, by country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Brazil companion diagnostics market, by technology
      • 6.5.2.1.2. Brazil companion diagnostics market, by indication
      • 6.5.2.2. South Africa
      • 6.5.2.2.1. South Africa companion diagnostics market, by technology
      • 6.5.2.2.2. South Africa companion diagnostics market, by indication
      • 6.5.2.3. Rest of LAMEA
      • 6.5.2.3.1. Rest of LAMEA companion diagnostics market, by technology
      • 6.5.2.3.2. Rest of LAMEA companion diagnostics market, by indication
    • 6.5.3. LAMEA market size and forecast, by technology
    • 6.5.4. LAMEA Market size and forecast, by indication

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
    • 7.1.1. Market player positioning, 2018
  • 7.2. Top winning strategies
  • 7.3. Competitive dashboard
  • 7.4. Competitive heatmap

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories Molecular, Inc.
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Product portfolio
    • 8.1.5. Business performance
    • 8.1.6. Key strategic moves and developments
  • 8.2. Agilent (Dako Denmark A/S)
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Product portfolio
    • 8.2.5. Business performance
    • 8.2.6. Key strategic moves and developments
  • 8.3. ARUP Laboratories, Inc.
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Service portfolio
  • 8.4. BioMerieux
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Product portfolio
    • 8.4.5. Business performance
  • 8.5. Danaher Corporation (Leica Microsystems)
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Product portfolio
    • 8.5.5. Business performance
  • 8.6. Foundation Medicine, Inc.
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Service portfolio
    • 8.6.5. Key strategic moves and developments
  • 8.7. Myriad Genetics, Inc.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Product portfolio
    • 8.7.5. Business performance
    • 8.7.6. Key strategic moves and developments
  • 8.8. Roche (Ventana Medical Systems, Inc)
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Product portfolio
    • 8.8.5. Business performance
    • 8.8.6. Key strategic moves and developments
  • 8.9. Thermo Fisher Scientific (Life Technologies Corporation)
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Product portfolio
    • 8.9.5. Business performance
    • 8.9.6. Key strategic moves and developments
  • 8.10. QIAGEN N.V.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Product portfolio
    • 8.10.5. Business performance
    • 8.10.6. Key strategic moves and developments

List of Tables

  • TABLE 01. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026 ($MILLION)
  • TABLE 02. IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 03. POLYMERASE CHAIN REACTION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 04. NEXT GENERATION SEQUENCING MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 05. IN SITU HYBRIDIZATION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 06. OTHERS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 07. GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026 ($MILLION)
  • TABLE 08. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TYPE, 2018-2026 ($MILLION)
  • TABLE 09. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 10. COMPANION DIAGNOSTICS FOR NEUROLOGY MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 11. COMPANION DIAGNOSTICS FOR OTHERS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 12. COMPANION DIAGNOSTICS MARKET REVENUE, BY REGION, 2018-2026 ($MILLION)
  • TABLE 13. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 14. U.S. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 15. U.S. COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 16. CANADA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 17. CANADA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 18. MEXICO COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 19. MEXICO COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 20. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 21. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 22. EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 23. GERMONY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 24. GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 25. FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 26. FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 27. UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 28. UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 29. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 30. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 31. EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 32. EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 33. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 34. JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 35. JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 36. CHINA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 37. CHINA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 38. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 39. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 40. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 41. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 42. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 43. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 44. LAMEA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 45. BRAZIL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 46. BRAZIL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 47. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 48. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 49. REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 50. REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 51. LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 52. LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 53. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 54. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 55. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 56. AGILENT: COMPANY SNAPSHOT
  • TABLE 57. AGILENT: OPERATING SEGMENTS
  • TABLE 58. AGILENT: PRODUCT PORTFOLIO
  • TABLE 59. ARUP LABORATORIES: COMPANY SNAPSHOT
  • TABLE 60. ARUP LABORATORIES: SERVICE PORTFOLIO
  • TABLE 61. BIOMERIEUX: COMPANY SNAPSHOT
  • TABLE 62. BIOMERIEUX: OPERATING SEGMENTS
  • TABLE 63. BIOMERIEUX: PRODUCT PORTFOLIO
  • TABLE 64. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 65. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 66. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 67. FOUNDATION MEDICINE: COMPANY SNAPSHOT
  • TABLE 68. FOUNDATION MEDICINE: SERVICE PORTFOLIO
  • TABLE 69. MYRIAD GENETICS, INC: COMPANY SNAPSHOT
  • TABLE 70. MYRIAD GENETICS, INC: OPERATING SEGMENTS
  • TABLE 71. MYRIAD GENETICS, INC: PRODUCT PORTFOLIO
  • TABLE 72. ROCHE: COMPANY SNAPSHOT
  • TABLE 73. ROCHE: OPERATING SEGMENTS
  • TABLE 74. ROCHE: PRODUCT PORTFOLIO
  • TABLE 75. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 76. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 77. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 78. QIAGEN N.V: COMPANY SNAPSHOT
  • TABLE 79. QIAGEN N.V: OPERATING SEGMENTS
  • TABLE 80. QIAGEN N.V: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. TOP INVESTMENT POCKETS IN THE GLOBAL COMPANION DIAGNOSTICS MARKET
  • FIGURE 02. TOP IMPACTING FACTORS
  • FIGURE 03. COMPANION DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 04. MARKET EVOLUTION/ INDUSTRY ROADMAP
  • FIGURE 05. IMPACT ANALYSIS
  • FIGURE 06. COMPARATIVE ANALYSIS OF IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 07. COMPARATIVE ANALYSIS OF POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 08. COMPARATIVE ANALYSIS OF NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 09. COMPARATIVE ANALYSIS OF IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 10. COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 11. COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 12. COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR NEUROLOGY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 13. COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 14. MARKET PLAYER POSITIONING, 2018
  • FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2019* (%)
  • FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2018-2019*
  • FIGURE 17. COMPETITIVE DASHBOARD
  • FIGURE 18. COMPETITIVE HEATMAP OF KEY PLAYERS
  • FIGURE 19. ABBOTT LABORATORIES: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 20. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 21. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 22. AGILENT: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 23. AGILENT: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 24. AGILENT: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 25. BIOMERIEUX: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 26. BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 27. BIOMERIEUX: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 28. DANAHER CORPORATION: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 29. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 30. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 31. MYRIAD GENETICS, INC: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 32. MYRIAD GENETICS, INC: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 33. ROCHE NET SALES, 2016-2018 ($MILLION)
  • FIGURE 34. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 35. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 36. THERMO FISHER SCIENTIFIC: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 37. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 38. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 39. QIAGEN N.V: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 40. QIAGEN N.V: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 41. QIAGEN N.V: REVENUE SHARE BY REGION, 2018 (%)
Back to Top